Published on 15 Jul 2021 on Bloomberg
Moderna Climbs as S&P 500 Set to Welcome Covid Vaccine Maker
The company, whose messenger-RNA vaccine has helped to fight the Covid-19 pandemic, will replace ...
Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag
Bayer Aktiengesellschaft’s BAYRY wholly owned subsidiary, BlueRock Therapeutics LP, announced tha...
Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?
The market expects Alexion Pharmaceuticals (ALXN) to deliver a year-over-year increase in earning...
ALXN vs. TECH: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably al...
Moderna Enters the S&P Amid Delta Variant Fears – Should You Invest?
Moderna entered the S&P 500 today, amid increasing global fears around the Delta variant. The sto...
Moderna stock 'has taken on a life of its own,' jumps 4% in S&P debut
Moderna (MRNA) began trading on the S&P 500 on Wednesday, replacing Alexion Pharmaceuticals Inc. ...
Moderna being added to S&P 500
The biotech company, which has already delivered over 100 million COVID-19 vaccines, will replace...
Alexion Pharmaceuticals Inc. stock outperforms market on strong trading day
Shares of Alexion Pharmaceuticals Inc. advanced 1.70% to $182.50 Tuesday, on what proved to be an...
Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study
Alexion Pharmaceuticals, Inc. ALXN announced that the late-stage study evaluating its long-acting...
Moderna to join S&P 500, shares jump after hours
Moderna Inc (MRNA.O) will join the S&P 500 index (.SPX) as of the start of trading on July 21, re...
Moderna Climbs as S&P 500 Set to Welcome Covid Vaccine Maker
The company, whose messenger-RNA vaccine has helped to fight the Covid-19 pandemic, will replace ...